<DOC>
	<DOCNO>NCT02184234</DOCNO>
	<brief_summary>Main objective : Safety tolerability Antistax® film coat tablet Secondary objective : Effect Antistax® film coat tablet subjective symptom chronic venous insufficiency</brief_summary>
	<brief_title>Tolerability Antistax® Patients Suffering From Chronic Venous Insufficiency ( CVI )</brief_title>
	<detailed_description />
	<mesh_term>Venous Insufficiency</mesh_term>
	<criteria>Chronic venous insufficiency stage I II accord Widmer , e.g. , result lowerleg oedema Male female outpatient ethnic origin Age range 25 75 year Known hypersensitivity ingredient study medication Oedema ( ) nonvenous origin , e.g. , due cardiac insufficiency , lymphoedema decompensated cardiac insufficiency , orthopaedic disturbance Florid venous ulcer Arterial occlusive disease , irrespective severity Phlebitis thrombophlebitis Clinical indication acute phlebologic intervention , e.g. , compressive treatment , phlebectomy , etc . Evidence diabetic microangiopathy polyneuropathy medical history Poor general health ( base investigator 's judgement ) Addiction alcohol abuse Mental illness inability ( limited ability ) work , inability ( limited ability ) follow speak write explanation concern trial Women childbearing age use reliable contraceptive method Pregnant lactating woman Patients previously enrol present study participate another clinical study , take part another study within previous 90 day Patients receive compression therapy , highceiling diuretic ( e.g. , furosemide ) , antiCVI preparation ( e.g. , vasoprotectives treat varicosis , heparincontaining preparation , sclerosing agent , bioflavonoids study medication ) trial . Medications measure CVI stop 14 day prior intake study medication .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>